Breast Cancer Clinical Trial
Official title:
Partial Breast Re-Irradiation for Patients With Ipsilateral Breast Tumor Recurrence, After First Being Treated With Breast Conservation for Early Stage Breast Cancer: An Efficacy Trial Comparing Mammosite® and Intraoperative Radiation
Verified date | August 2020 |
Source | Case Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill
tumor cells. It is not yet known whether a single dose of radiation therapy is more effective
than implant radiation therapy for 5 days in treating patients with recurrent breast cancer.
PURPOSE: This phase II trial is studying implant radiation therapy to see how well it works
compared with radiation therapy during surgery in treating patients with recurrent breast
cancer.
Status | Completed |
Enrollment | 13 |
Est. completion date | July 6, 2018 |
Est. primary completion date | July 6, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies. - Lesion size = 3 cm treated with a tylectomy and whole breast irradiation (with or without tumor bed boost) - Unifocal breast cancer recurrence - Negative resection margins with at least a 2 mm margin from invasive and in situ cancer or a negative re-excision - Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation. - Signed study-specific informed consent prior to study entry. Exclusion Criteria: - Patients with distant metastatic disease - Patients with invasive lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or nonepithelial breast malignancies such as lymphoma or sarcoma. - Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative. - Extensive intraductal component (EIC) by the Harvard definition, i.e. 1) more than 25% of the invasive tumor is Ductal carcinoma in situ (DCIS) and DCIS present in adjacent breast tissue. Presence of an EIC increases the chance of local recurrence, and as such, one might not be a candidate for repeat breast conservation. - Patients with Paget's disease of the nipple. - Patients with skin involvement. - Patients with collagen vascular disorders, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis. - Patients with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent. - Other malignancy, except non-melanomatous skin cancer, < 5 years prior to participation in this study. - Patients who are pregnant or lactating due to potential fetal exposure to radiation and unknown effects of radiation on lactating females. - Patients with known BReast CAncer gene (BRCA)1/BRCA 2 mutations. |
Country | Name | City | State |
---|---|---|---|
United States | UHHS Chagrin Highlands Medical Center | Cleveland | Ohio |
United States | UHHS Westlake Medical Center | Cleveland | Ohio |
United States | University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 1 month after radiation therapy (RT) | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 3 months after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 6 months after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 9 months after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 12 months after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 2 years after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 3 years after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 4 years after RT | |
Primary | Ipsilateral Breast Tumor Recurrence Rates | Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. | 5 years after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 1 month after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 3 month after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 6 month after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 12 month after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 2 years after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 3 years after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 4 years after RT | |
Primary | Tumor Bed Recurrence Rates | Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision | 5 years after RT | |
Primary | Cosmetic Outcome as Determined by an Established Scale | Cosmetic outcome as determined by four-level scale of cosmetic outcome scale, with levels poor, fair, good, and excellent in increasingly positive outcomes. Excellent: Minimal or no difference in the size or shape of the treated breast Good: Slight difference in the size or shape of the treated breast Fair: Obvious difference in the shape and size of the treated breast Poor: Obvious difference in the shape and size of the treated breast |
1 month after RT & Q3mos for one year and at 5 years | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
1 month after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
3 month after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
6 month after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
9 month after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
12 month after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
2 years after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
3 years after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
4 years after RT | |
Primary | Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey | Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is" I am totally satisfied with the treatment and results I am not totally satisfied but would choose the same treatment again. I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again. I am dissatisfied with my treatment. |
5 years after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 1 month after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 3 month after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 6 month after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 9 month after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 12 month after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 2 years after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 3 years after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 4 years after RT | |
Primary | Percent of Participants Experiencing Complications After Intervention | Overall complication rate, as measured by percent of participants experiencing complications after intervention | 5 years after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 1 month after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 3 month after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 6 month after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 9 month after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 12 month after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 2 years after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 3 years after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 4 years after RT | |
Secondary | Percent of Participants With Delayed Wound Healing | Wound healing rate, as measured by percent of participants with delayed wound healing | 5 years after RT |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |